LifeArc invests in Exciva’s €51 million ($59m) Series B funding round

“Congratulations to Exciva on closing its €51 million Series B financing. Exciva is addressing a major unmet need in Alzheimer’s disease with a highly differentiated approach for patients with limited treatment options. We were impressed by the strength of the science and the team’s deep neuropsychiatric and drug development expertise. LifeArc Ventures is pleased to join a strong international syndicate, including Gimv, EQT Life Sciences, Fountain Healthcare Partners, Carma Fund and Modi VC, alongside existing investors Andera Partners and LBBW, in supporting Exciva as Deraphan enters Phase 2 clinical trials.”

Jonathan Nash, Investment Principal, LifeArc Ventures

Read the post here